HYMER-ERIBA ML-T CrossOver 570 KDV ayrıştırılabilir

Gelenekten Gelen Yetkinlik
30 yıldan fazladır B1'deki Hymer Merkezi - Hymer, Niesmann+Bischoff, Carado ve Eriba markaları konusunda yetkin ortağınız
Her zaman tüm düzenler önceden mevcuttur - tüm yeni, ön inceleme, ikinci el ve fuar araçları şurada: www.hymerb1.de

• ---* Motor / Şasi: Mercedes Sprinter 2,0

* Güç: 140 kW / 190 PS
* Şanzıman: Otomatik
* Kilometre: 19168 km
* İzin verilen toplam ağırlık: 4100 kg
* Yatak(lar): Tek yataklı yataklar
* Oturma grubu: L-oturma grubu
* Döşeme: Deri Lund
* Ahşap dekor: Native Bamboo

• ---ÖZEL EKIPMAN:

* Araç 02/24 - 07/26 döneminde Hymer AG Bad Waldsee basın araç filosunda kayıtlı idi - KDV ayrıntılı olarak belirtilebilir, ek garantı mevcuttur. COC belgeleri mevcut
* MLT 570 Crossover Edisyon donanımı: TEMEL / ŞASI Mercedes-Benz Sprinter 4,1 t - 419 CDI - 140 KW/190 PS - Euro VI-E Şoför kabini dış rengi Tenoritgrau (Metalik) Gövde dış rengi Crystal-Silver-Metallic Daimi dört çeker çekiş 93 litre yakıt tankı dahil 9G-TRONIC otomatik şanzıman Hold fonksiyonu dahil (x19 CDI) Krom ızgarası LED Yüksek Performanslı Farlar Sis farları ve dönüş ışığı Tampon, aksesuarlar ve ızgara çerçevesi araç renginde boyalı Isıtılabilir ön cam 16" çelik jantlar (siyah) off-road lastikleriyle (All-Terrain) 16" çelik yedek tekerlek off-road lastikleriyle (All-Terrain) ve arka duvarın dışında tutucu Kablosuz şarj işlevi ve şarj durumu göstergesi dahil akıllı telefon depolama alanı Yükleme paketi 2 x USB-C konektörlü alet tablosu 5V / 1 x 12V soket Deri direksiyon (otomatik şanzıman ile) MBUX 10,25" Multimedya sistemi geri görüş kamerası, sesli kontrol ve dokunmatik ekran dahil navigasyon ve akıllı telefon entegrasyonu Tamamen otomatik THERMOTRONIC klima Aktif Mesafe Asistanı DISTRONIC PLUS direksiyon çok fonksiyonlu düğmeler dahil Aktif Şerit Tutma Asistanı Uzak Işık Asistanı Trafik İşareti Asistanı DIŞ / İÇ Adaptörlü tenta, gümüş gövde, 400 x 250 cm Çatı rayı ve arka merdiveni çatı plakası olmaksızın Alüminyum çatı paneli LED Işık barı 11" Motor / Alt koruma Ön tekerlek kemer genişletmesi Pencereli konforlu giriş kapısı, karartma panjuru, entegre çöp kutusu ve 2 katlı kilit DIŞ / İÇ Arka garajda oluklu metal döşeme ve keçe kaplama Garajda dış duş Araç seti (katlanabilir kürek, balta) arka depolama alanında Konforlu L-oturma grubu lounge döşemesi ile, boyuna/enine kaydırılabilir tablo ve 2 entegre 3 noktalı emniyet kemeri Konforlu L-oturma grubu için yatak yapısı alçaltılabilir masalı Yatak rahat sistemi tel yatak ve çok bölgeli soğuk köpük yatak(lar) arka yatak(lar) için Arka yataklar için ölçüye göre yapılmış çarşaf bireysel olarak yatak döşeğine uyarlanmış Uzun tek yataklı yataklar arasında çıkış merdivenli ekstra döşeme Thermo Fisher Scientific Inc. is one of the world's leading biotechnology companies, serving customers globally in the life sciences, analytical, and specialty diagnostics markets. The company offers a broad array of reagents, instruments, and software solutions that span the breadth of the scientific discovery spectrum. In recent years, it has been making significant investments to strengthen its scientific capabilities, including acquiring some of the biggest companies in the life sciences sector. One such acquisition is the company's investment in the GeneChip® assay technologies developed by Affymetrix Inc., now a part of Thermo Fisher Scientific. Through the GeneChip assay technology platform, Thermo Fisher provides microarray-based gene expression analysis platforms that have been used by research scientists worldwide for the past two decades. Thermo Fisher Scientific Inc. invests significantly in providing alternative molecular biology platforms for different applications, customer segments, and price points. Through continuous development and innovation, Thermo Fisher develops next-generation sequencing (NGS) platforms, PCR-based gene expression platforms, digital PCR platforms, and other molecular biology solutions. Thermo Fisher Scientific through its various business units has the ability and commitment to support customers with comprehensive solutions that integrate instrumentation, reagents, and informatics. Thermo Fisher Scientific Inc. has a diversified customer base including academic institutions, research centers, diagnostic laboratories, drug discovery and development companies, and biotechnology companies. Thermo Fisher Scientific can provide customers with many solutions for investigating diseases, improving quality control practices, drug discovery and development processes, and enhancing research capabilities. Thermo Fisher Scientific Inc. has a large installed base of research scientists and customers who use various platforms for their molecular biology research. The company has a global organization that provides technical support for its customers worldwide, especially through its local offices and research centers.

For details about the current status of Affymetrix, please see the official Thermo Fisher website.

Founded in 1956, Affymetrix Inc. was a pioneer in developing microarray-based gene expression analysis platforms. Over the past decades, Affymetrix served as an important resource for researchers and diagnosticians worldwide. Affymetrix developed microarray platforms that include GeneChip® Arrays, a comprehensive portfolio of tools and services that allow researchers and diagnosticians to investigate gene expression patterns, genetic variations, and genetic markers relevant to disease states, drug responses, and other areas of scientific and medical research. The company provided a full spectrum of integrated solutions, including microarrays, reagents, and bioinformatics software. After being acquired by Thermo Fisher Scientific in 2016, Affymetrix became part of the larger Thermo Fisher organization, bringing its microarray expertise to a broader portfolio of molecular biology solutions.

The main research application areas for GeneChip® assays include:

• Gene expression profiling
• Genotyping
• Copy number variation (CNV) analysis
• miRNA profiling
• Whole genome association studies (WGAS)

GeneChip® arrays are microarrays - high-throughput platforms that enable simultaneous analysis of thousands of genes (or genetic markers) in a single experiment. The microarray format allows researchers to analyze large amounts of genomic information in a relatively simple and efficient manner.

The GeneChip® product line includes various array types

• Expression Arrays - these measure messenger RNA (mRNA) levels across tens of thousands of genes
• SNP (Single Nucleotide Polymorphism) Arrays - these detect genetic variations and are used for genotyping applications
• CGH (Comparative Genomic Hybridization) Arrays - these are used for copy number variation analysis

One of the key advantages of GeneChip® arrays is their utility in working with small sample sizes, even as little as nanograms of starting material. Another important advantage is the cost-effectiveness of the platform, especially when analyzing large numbers of samples. GeneChip® assays also offer the advantage of generating standardized, reproducible data that can be easily compared across experiments and laboratories.

In recent years, next-generation sequencing (NGS) technologies have begun to compete with and, in some applications, complement microarray-based approaches. Despite this competition, GeneChip® arrays continue to be widely used in research and diagnostics because of their reliability, robustness, and cost-effectiveness for many applications.

The GeneChip® microarray platform has been instrumental in advancing biomedical research. The platform has enabled many landmark discoveries, including studies that have contributed to understanding of gene regulation, disease mechanisms, and the effects of therapeutic interventions. Research using GeneChip® arrays has been published in thousands of peer-reviewed journals and has contributed significantly to scientific knowledge in genomics and personalized medicine.

GeneChip® arrays have been used in numerous clinical applications including:

• Pharmacogenomics - understanding how genetic variations affect drug responses
• Cancer research and diagnosis - identifying gene expression patterns associated with specific cancer types
• Infectious disease diagnosis - identifying pathogen-specific genetic signatures
• Prenatal and newborn screening - detecting genetic abnormalities

The company's commitment to innovation has also led to the development of other complementary technologies. These include:

• Digital PCR platforms
• NGS platforms
• qPCR-based gene expression platforms

In conclusion, Thermo Fisher Scientific Inc., through its ownership of the GeneChip® technologies, provides researchers and diagnosticians worldwide with powerful, reliable, and cost-effective tools for investigating genomic information. The continued use and evolution of GeneChip® arrays demonstrates the enduring value of this microarray platform in the fields of genomics research and molecular diagnostics.

This article was last updated in 2024.